BTAI
BioXcel Therapeutics, Inc.
Key Financials
Revenue
$642000
↓ 71.7%
Operating Income
$-50461000
↑ 25.0%
Net Income
$-69897000
↓ 17.3%
EPS (Diluted)
$-5.73
↑ 75.6%
Total Assets
$44.9M
↑ 17.2%
Shareholders' Equity
$-95463000.00
↓ 2.5%
Total Liabilities
$140.4M
↑ 6.8%
Cash & Equivalents
$28.4M
↓ 4.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 8/14/2026 | View on SEC |
| 3 | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 10-Q | 8/13/2026 | View on SEC |
| 8-K | 8/11/2026 | View on SEC |
| 8-K | 8/3/2026 | View on SEC |
| 8-K | 7/6/2026 | View on SEC |
| 4 | 6/17/2026 | View on SEC |
| 4 | 6/17/2026 | View on SEC |
| 4 | 6/17/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BTAI |
| Company Name | BioXcel Therapeutics, Inc. |
| CIK | 1720893 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 203-643-8060 |